adsilico
PrivateLast Round
Series A
Oct 26, 2026
Est. Valuation
$26.5M
Total Funding Raised
$17.8M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
adsilico operates in Healthcare & Life Sciences and is based in Leeds. Its latest recorded funding round was a Series A round in October 2026.
adsilico is a health technology company that provides an in-silico trials solution using computational modeling and simulation to test medical devices.
Sector
Healthcare & Life Sciences
Verticals
Clinical Trials, Medical Devices, Synthetic Data, Medical AI, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Usage-Based SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
adsilico Comparables
Compare adsilico with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Virtonomy.io | 84% | |
| ELEM Biotech | 83% | |
| DARERL | 83% |
For institutional investors. Book with your work email.
adsilico Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 26, 2026 | ||||
| Grant | Mar 1, 2024 | ||||
| Seed | Feb 26, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
adsilico Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| Northern Gritstone | Series A, Seed |
| Parkwalk Advisors | Series A, Seed |
| PXN Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 26, 2026
$13.4M round led by PXN Ventures.
- May 8, 2025
Grew 33% QoQ from 12 to 16 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 27, 2026
On Oct 27th '26, Adsilico Limited's £10 million Series A funding supports further development of the Virtual Chimera(TM) platform beyond cardiovascular applications into additional therapeutic areas, including neurovascular devices.
- receives_financingOct 26, 2026
Adsilico Limited receives $13.3M in Series A financing led by PXN Ventures, with participation from Northern Gritstone and Parkwalk, to expand its AI-powered simulation technology for testing medical devices on virtual patients in the United Kingdom.
For institutional investors. Book with your work email.
adsilico Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about adsilico's valuation, stock price, and market status.
Is adsilico a public or private company?
adsilico is a private company.
What is the current stock price of adsilico?
adsilico is a private company, so its shares have no public market price. Caplight tracks adsilico's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is adsilico worth (valuation)?
adsilico's valuation is estimated at $26.5M based on funding round data.
Can I buy adsilico stock?
adsilico shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was adsilico's last funding round?
adsilico's most recent funding round was Series A on October 26, 2026.
Who are the main investors in adsilico?
Key investors in adsilico include PXN Ventures.
Will adsilico IPO soon?
No public IPO plans have been announced for adsilico.
How can I track adsilico secondary market activity?
Caplight tracks bids, offers, and trades in adsilico's shares on secondary markets.